Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions.

Slides:



Advertisements
Similar presentations
Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.
Advertisements

ISTC Training Modules 2008 Your name Institution/organization Meeting Date.
Your name Institution/organization Meeting Date. Introduction.
TB Disease and Latent TB Infection
Improving diagnosis TB laboratory strengthening.
TREATMENT OF TUBERCULOSIS, 2003
Evaluation of Sputum Culture Conversion
Patient Initial Evaluation & Follow up. Pretreatment screening and evaluation: Initial evaluation serves to establish a baseline and may identify patients.
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
World Health Organization TB Case Definitions
INFECTION CONTROL MEASURES DOTS PLUS STRATEGY LRS Institute of Tuberculosis & Respiratory Diseases Sri Aurobindo Marg, New Delhi
Antimicrobial Resistance in N. gonorrhoeae – An Overview 2014 INTRODUCTION Progressive antimicrobial resistance in Neisseria gonorrhoeae is an emerging.
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
1 Constructing a regimen Session 5. USAID TB CARE II PROJECT Principles of designing an MDR-TB treatment regimen Include at least four second-line anti-TB.
7. Anti-TB regimen in special situations of liver disease, renal impairment, and pregnancy.
Antimicrobial Resistance in N. gonorrhoeae: In Brief 2014 INTRODUCTION Increased action is needed to help prevent and control gonorrhea. Worldwide antimicrobial.
Module 3: Drug-Resistant TB. Learning Objectives Describe how drug resistance emerges Explain the difference between primary and secondary resistance.
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
MDR and XDR TB Bruce A. Bush, M.D. Regional Tuberculosis Consultant
Status of Revised National Tuberculosis Control Program (RNTCP) in India Dr Jitendra.
Overview of current MDR-TB case definitions and treatment outcome Dennis Falzon Consultation : Impact of WHO-endorsed molecular diagnostics on TB and MDR-TB.
Clinical Pharmacy.  Tuberculosis is caused by M. tuberculosis, an aerobic, non–spore-forming bacillus that resists decolorization by acid alcohol after.
Treatment and Management. Stabilize the Patient Airway Breathing Circulation.
Management of MDR-TB patients in the hospital: LRS Institute Experience LRS Institute of TB and Respiratory Diseases Sri Aurobindo Marg, New Delhi.
How long is the duration of treatment for XDR-TB? At least 2 years (the same as MDR-TB). Doctors will monitor people with any form of confirmed drug resistant.
Christoph Lange & Giovanni Sotgiu Principles of designing a TB and MDR-TB drug regimen.
Plans for Diagnosis and Management of Acute Pyelonephritis.
Guidelines for chemotherapy of tuberculosis in Taiwan 馬偕紀念醫院 一般內科及感染科 主治醫師 曾祥洸
TB 101: TB Basics and Global Approaches. Objectives Review basic TB facts. Define common TB terms. Describe key global TB prevention and care strategies.
RNTCP: DOTS Expansion and plans for DOTS-Plus
Monitoring and Evaluation Module 12 – March 2010.
Extrapulmonary Site 2 :_____________________ Name (surname, first name) Age (in years) Sex F Alternative address Physical Address (in full) M INTERIM TUBERCULOSIS.
SUPRA-NATIONAL REFERENCE LABORATORY NETWORK Possible research projects A. Van Deun.
TB 101 Part II Brenda Mayes, R. N. March TREATMENT TB DISEASE MDR XDR LATENT TB INFECTION.
V IRGINIA C OHORT D ATA – 5 YEAR TRENDS AFTER 4 YEARS OF LOCAL COHORT REVIEW Virginia achievement on National TB Indicators for the past 5 years – where.
DOTS-PLUS IN TANZANIA: PREPARATION PHASE Global DOTS Expansion Working Group Meeting, Paris: 28 October 2004 NTLP - MOH Prepared by: Dr. S. M. Egwaga NTLP.
Revising the WHO TB Treatment Guidelines Process and new recommendations Malgosia Grzemska Matteo Zignol Stop TB Department World Health Organization DEWG.
Extrapulmonary Site 2 :_____________________ TUBERCULOSIS TREATMENT CARD BOTSWANA NATIONAL TUBERCULOSIS PROGRAMME Date RegisteredIN ToOUT RegisteredIN.
Trials and evidence in relation to health policy: The case of tuberculosis in Nepal and India Ian Harper.
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
TB Prevention and Control in Correctional and Detention Facilities Mark Lobato, MD Division of TB Elimination Centers for Disease Control and Prevention.
TREATMENT of TB in ADULTS
MULTIDRUG- RESISTANT TUBERCULOSIS (MDR-TB) by Dr Mat Zuki Mat Jaeb 1.
FOLLOW-UP, REFERRAL & COMMON ADR OF ANTITB TREATMENT by Assoc. Prof. Dr. Tengku Saifudin Tengku Ismail Ms. Rahela Ambaras Khan 1.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
Novel Regimen Options for DR-TB Treatment
TREATMENT OF TUBERCULOSIS: Prevention: BCG vaccination: It does not prevent infection but limits multiplication and spread of following infection so prevents.
Case Holding (TB-DOTS Training). Case holding a set of procedures which ensures that patients complete their treatment involves assignment of the appropriate.
Evaluation of a Standardized Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (ST REAM) Nehemiah Nhando UZ-UCSF ANNUAL RESEARCH DAY.
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
Antituberculous treatment.
Treatment for Multi-drug Resistant TB
STREAM Trials Andrew Nunn MRC Clinical Trials Unit at UCL
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
Infant born with mother Tuberculosis
Treatment of TB Disease
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
بسم الله الرحمن الرحيم.
Marie Turner, M.D. Jo-Ann Keegan, R.N., M.S.N.
Kandeke C, Chibuta C, Banda D
Richard Laing, Kelly McGoldrick
Tuberculosis in children BY MBBSPPT.COM
New Hampshire Training Cohort
Goal Objectives Expected Outcomes
CASE HOLDING FOR PMDT.
Treatment of Drug Resistant TB - Questions
Presentation transcript:

Group II Treatment regimens, hospitalization. DOT provision, outcome definitions, management of adverse drug reactions

Presumptions at the onset …before we start, we presume that group-I’s recommendations would probably include the following: The intake would be of only Cat II failures from RNTCP – DOTS PLUS RNTCP accredited labs would do the smear and culture results for investigations and follow-up The Drug Sensitivity testing (investigation stage) would be done for the following drugs only: HRES

Requirement for hospitalisation It is recommended all patients be admitted to the designated specialised institution for at least 2 to 4 weeks with the objective to: –Undertake necessary investigations –Initiate MDRTB treatment –Monitor drug tolerance –Motivation, counseling, health education –Developing linkages in the field –Contact assessment Subsequent hospitalisation may be required for management of ADR, complications and to assess need for surgical intervention, social reasons etc

STR versus ITR STR was chosen for operational reasons

Number of drugs in IP The “HR resist. only” group and “HR+one drug resist” group together would probably constitute more than 60% in any given cohort of MDR cases Therefore a five drug IP regimen would give an armamentarium of at least four effective drugs to most patients One drug would be kept as reserve as a fall-back choice in case any adverse drug reaction necessitated withdrawal of one drug One injectable and four oral drugs

IP regimen - Aminoglycoside The group felt that Kanamycin was the better choice for Aminoglycoside: –Only about 50% of patients who have taken RNTCP cat II are likely to be sensitive to streptomycin –It may not be possible to give streptomycin for 9 months as the vestibulo-cochlear toxicity would be too much –Capreomycin is prohibitively costly and difficult to store To minimise cross resistance: decision is to be taken as such: If resistant to SM Kana/Amikacin; If resistant to Kana/ Amika use Capreo.

IP regimen - Quinolones The group noted that quinolones especially Oflox and Ciproflox are used universally in OPDs in the country for common illnesses like URI, pyrexia etc. However the limited literature available shows that resistance to quinolones in India is very less Ofloxacin was recommended as the drug of choice for the DOTS plus regimen because of: –Most widely studied drug in MDR-TB –Less toxicity as compared to newer quinolones like Gatiflox and Moxiflox (Gati & Moxi need CCT in Indian scenario) –Cost factor - affordable –Availability

IP Regimen – Others Ethionamide – Cheap, available, tolerance good Pyrazinamide – Only drug which acts in acidic pH Ethambutol – The group raised concerns about the standardisation of Etambutol resistance; however ethambutol is a valuable drug to be used in IP Thiacetazone is not available any more; bacteriostatic The following were kept as reserve drugs in case of resistance/ intolerance to any drug: 1.PAS – Toxic, doubtful bio-availability in some, bacteriostatic Will be kept as a reserve drug 2.Cycloserine – Bacteriostatic, Toxicity is too much: Therefore it is not being included as mainline drug.– will be kept as second reserve drug

The agreed to IP regimen consists of : Five mainline drugs: –Kanamycin –Ofloxacin –Ethionamide –Pyrazinamide –Ethambutol One reserve drug: –PAS –Cycloserine

IP regimen: Modality of administration All drugs would be given as Daily DOT for 6 days a week; EVERY DOSE IN DOTS PLUS SHOULD BE SUPERVISED

IP regimen- Duration The group came to the consensus that the intensive phase should be given for a minimum duration of 6 months, upto 9 months. Monthly sputum smear examination and sputum culture would be conducted to monitor response to therapy IP regimen would be given till at least three consecutive negative smears AND last available culture is negative. If the above two results are not available, IP will be extended till such result is obtained; upto a maximum of 9 months Decision to stop IP and start CP will be ratified by the hospital’s DOTS Plus Committee In rare cases where the patient remains sputum positive by culture at 9 month and patient is tolerating injectable drugs, injectable will continue till sputum conversion???

CP- Duration The group recommends that the continuation phase should be: -for at least 18 months after culture conversion CP- Drugs The three drugs are: Ethionamide, Ofloxacin, Ethambutol These are to be given as daily doses for 6 days a week; all doses would be DOT Intolerance to any drug in CP: offending drug may be replaced by PAS/ Cycloserine

DOTS Plus regimen: Dosages The average body weight of the MDR TB patient in India is 40 kgs. So two weight bands are recommended: Drugs< 40 kg body wt.> 40 kg body wt. Kanamycin 500 mg750 mg Ofloxacin 600 mg800 mg Ethionamide 500 mg750 mg Ethambutol 800 mg1200 mg Pyrazinamide 1500 mg1750 mg PAS 10 gm12 gm Cycloserine 500 mg750 mg

Outcome Definitions Cure : Patient has completed treatment and is culture negative for the last 12 months of treatment. A single intervening positive culture should be ignored provided it is followed by 3 consecutive negative cultures. Treatment completed. A patient who has completed entire treatment but due to lack of bacteriological results does not fulfill the definitions of cure Default: A patient who interrupted treatment for two or more consecutive months Death: A patient who died from any cause during treatment

Outcome Definitions Failure: A patient with more than one positive culture in the last 12 months of treatment with a minimum of five cultures performed in last 12 months. A patient will also be considered treatment failure if one of the last three culture during treatment is positive or if he/she is persistently culture positive and decision has been taken to terminate treatment early by the DOTS plus committee. Adverse reactions: A patient who could not continue STR due to severe adverse drug reactions as decided by the DOTS plus committee

Outcome Definitions Transfer out: A patient has been transferred to another MDR-TB unit and whose outcome will be reported by the receiving unit Still on treatment: A patient who is still on treatment at the time of the cohort reporting

Adverse drug reactions The document circulated by TRC endorsed by the group RNTCP should make provisions for making ancillary drugs available Training on management of ADR should be incorporated at all levels Decision to change/stop treatment should be by the DOTS plus committee

MDRTB- special situations MDRTB with pregnancy MDRTB in Pediatric/EP site MDRTB with HIV infection MDRTB in patients with renal/hepatic failure Preventive therapy to paediatric and adult contacts